Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Kalkine 0
countryflagAU

Memphasys Ltd

Healthcare AU MEM

0.004AUD
-0.001(20.00%)

Last update at 2025-07-11T00:46:00Z

Day Range

0.0040.004
LowHigh

52 Week Range

0.0040.01
LowHigh

Fundamentals

  • Previous Close 0.005
  • Market Cap9.92M
  • Volume129000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.74765M
  • Revenue TTM1.07M
  • Revenue Per Share TTM0.001
  • Gross Profit TTM 0.93M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -3.40262M -2.08196M -1.48643M -1.13388M -1.04458M
Minority interest - - - - -
Net income -3.40262M -2.08196M -1.48643M -0.97641M -1.09191M
Selling general administrative 0.58M 1.09M 1.24M 1.15M 0.89M
Selling and marketing expenses 0.15M 0.11M - - -
Gross profit 0.00922M 0.00824M 0.00824M - -
Reconciled depreciation 0.61M 0.12M 0.26M 0.20M 0.00892M
Ebit -3.08584M -1.62931M -1.46109M -1.45796M -0.99724M
Ebitda -2.47300M -1.50609M -1.20161M -1.26173M -0.98832M
Depreciation and amortization 0.61M 0.12M 0.26M 0.20M 0.00892M
Non operating income net other - - - - -
Operating income -2.76149M -1.96653M -1.46109M -1.45796M -0.99724M
Other operating expenses 3.60M 2.05M 1.96M 1.46M 1.09M
Interest expense 0.32M 0.45M 0.03M 0.04M 0.05M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.39M 0.00071M 0.00254M 0.03M 0.00288M
Net interest income -0.41494M -0.56597M -0.08697M -0.06860M -0.04446M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.96M 1.67M 0.33M -0.15747M 0.05M
Total revenue 0.02M 0.03M 0.03M 0.00000M 0.00000M
Total operating expenses 3.64M 2.74M 1.96M 1.46M 1.09M
Cost of revenue 0.00615M 0.02M 0.02M - -
Total other income expense net 0.65M 1.22M 0.30M 0.32M -0.04733M
Discontinued operations - - - - -
Net income from continuing ops -3.40262M -2.08196M -1.48643M -1.13388M -1.04458M
Net income applicable to common shares -3.40262M -2.08196M -1.48643M -1.13388M -1.04458M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 12.43M 14.67M 14.12M 14.58M 11.30M
Intangible assets - 10.29M 9.68M 8.29M 6.55M
Earning assets - - - - -
Other current assets 1.18M 1.36M 1.55M 1.57M 1.39M
Total liab 5.59M 7.28M 6.47M 5.97M 1.54M
Total stockholder equity 6.84M 7.38M 7.65M 8.61M 9.76M
Deferred long term liab - - - - -
Other current liab 0.24M 5.45M 4.41M 0.70M -0.00301M
Common stock 57.28M 53.42M 50.34M 48.88M 48.70M
Capital stock - 53.42M 50.34M 48.88M 48.70M
Retained earnings -50.43009M -46.17323M -42.77061M -41.16742M -39.68099M
Other liab - 0.00136M 0.03M 0.03M 0.03M
Good will - - - - -
Other assets - - - - -
Cash 0.28M 0.64M 0.27M 2.00M 1.97M
Cash and equivalents - - - - -
Total current liabilities 5.25M 5.57M 4.54M 0.86M 0.59M
Current deferred revenue 0.07M -4.65768M -3.65939M -0.26886M 0.23M
Net debt 4.48M 5.73M 5.29M 3.35M -0.90056M
Short term debt 4.42M 4.66M 3.66M 0.27M 0.14M
Short long term debt - 4.55M 3.56M 0.18M 0.03M
Short long term debt total 4.76M 6.37M 5.56M 5.36M 1.07M
Other stockholder equity -0.01245M -7.24456M -7.57033M -7.71675M -9.01675M
Property plant equipment - 2.10M 2.34M 2.60M 1.19M
Total current assets 1.62M 2.25M 2.03M 3.69M 3.56M
Long term investments - 0.03M 0.07M - -
Net tangible assets - -2.91005M -2.03224M 0.32M 3.21M
Short term investments - 0.04M - - -
Net receivables - 0.12M 0.12M 0.01M 0.17M
Long term debt - - 0.08M 3.16M -
Inventory 0.16M 0.13M 0.09M 0.12M 0.03M
Accounts payable 0.52M 0.12M 0.13M 0.16M 0.22M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.14M 0.08M 0.89M 0.74M
Additional paid in capital - - - - -
Common stock total equity - - - - 48.70M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 10.09M -12.41911M -12.09258M -10.89206M -7.74085M
Deferred long term asset charges - - - - -
Non current assets total 10.81M 12.42M 12.09M 10.89M 7.74M
Capital lease obligations - 1.83M 1.92M 2.01M 1.04M
Long term debt total - 1.71M 1.83M 4.86M 0.93M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -1.97670M -3.07778M -3.00155M -3.11031M -2.12369M
Change to liabilities -0.00426M 1.89M 1.41M 1.23M 1.09M
Total cashflows from investing activities -1.97670M -3.07778M -3.00155M -3.11031M -2.12369M
Net borrowings 0.68M -0.01317M 2.81M -0.09227M 1.18M
Total cash from financing activities 3.75M 1.03M 2.99M 4.11M 3.50M
Change to operating activities 1.93M 0.86M 0.09M 0.17M -0.00538M
Net income -3.40262M -2.08196M -1.48643M -1.13388M -1.09191M
Change in cash 0.37M -1.73384M 0.04M 1.09M 0.67M
Begin period cash flow 0.27M 2.00M 1.97M 0.87M 0.20M
End period cash flow 0.64M 0.27M 2.00M 1.97M 0.87M
Total cash from operating activities -1.40667M -0.36885M 0.04M 0.09M -0.70747M
Issuance of capital stock 3.36M 1.08M 0.19M 4.54M 2.70M
Depreciation 0.12M 0.12M 0.26M 0.20M 0.00892M
Other cashflows from investing activities -0.15467M -0.15467M 0.00254M 0.03M 0.00288M
Dividends paid 0.85M 0.07M 2.97M 0.07M -
Change to inventory -0.04370M 0.03M -0.08612M -0.03268M -0.03268M
Change to account receivables - - - -0.27727M -0.62058M
Sale purchase of stock -0.28357M -0.03053M -0.00613M -0.33990M -0.38003M
Other cashflows from financing activities 1.60M -0.01317M 5.84M -0.09227M 1.34M
Change to netincome -0.49708M -0.54806M -0.14158M -0.05104M -0.12855M
Capital expenditures 1.82M 2.92M 3.00M 3.14M 2.13M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.04370M 0.03M -0.08612M -0.03268M 0.59M
Stock based compensation 0.09M 0.07M 0.14M 0.28M -
Other non cash items 1.88M 1.59M 1.27M 1.03M 1.04M
Free cash flow -3.22870M -3.29197M -2.95939M -3.04489M -2.12656M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MEM
Memphasys Ltd		 -0.001 20.00% 0.004 - - 9.23 1.63 494.48 -11.1564
CSL
CSL Ltd		 -1.49 0.61% 240.92 28.85 32.79 7.69 4.14 5.94 18.43
TLX
Telix Pharmaceuticals Ltd		 -0.38 1.55% 24.09 163.67 47.85 10.52 14.41 10.29 87.11
MSB
Mesoblast Ltd		 0.01 0.61% 1.66 - 454.55 369.57 2.96 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.04 0.27% 14.57 13.39 35.21 8.48 5.06 7.81 9.49

Reports Covered

Stock Research & News

View All

Profile

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company primarily develops Felix, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid oxidative stress assay; and AI-Port. In addition, the company offers ambient temperature storage product for human sperm. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.

Memphasys Ltd

34 Richmond Road, Homebush, NSW, Australia, 2140

Key Executives

Name Title Year Born
Ms. Alison Mary Coutts B.E., B.E. (Chem), GDipBiotech, M.B.A., MBA MD, CEO & Director NA
Pablo Neyertz Director of Fin. NA
Nick Gorring Operations Mang. NA
Mr. Malcolm Coleman Chief Financial Officer of Nusep Ltd NA
Mr. Andrew Metcalfe B.Bus, CPA, FGIA, MAICD Company Sec. NA
Dr. David Ali Acting CEO & Executive Director NA
Pablo Neyertz Director of Finance NA
Associate Prof. Hassan Bakos Director of Operations NA
Prof. R. John Aitken Ph.D., ScD FRSE Scientific Director NA
Mr. Andrew Metcalfe B.Bus, CPA, FGIA, MAICD Company Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.